Pharma Market Access Insights - from Petauri Evidence

• Communicating value to US Payers: Insights for Pharma and Medtech

  Send us a textWhat do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging resonates in the US? How do you prepare for launch in a market as diverse as the US?In this Global Whispers episode, Louise Maddison (Senior Consultant – Global Market Access, Petauri Evidence) interviews some of our colleagues from Petauri Advisors who are either former payers, or former industry market access leads in the US. Louise puts your questions to: - Rory Davies – Vice President of Value and Access, Petauri Advisors, with extensive past experience in Chief Clinical roles at Cigna, Flipt and WellDyne - Dan Vanderpoel – Executive Vice President, Strategic Payer Marketing; Head, Client Solutions, Petauri and former Manager, Trade Relations at Humana - Shana Gunderson Hua – Vice President of Value and Access, Petauri Advisors and former Medical Affairs Executive Director at Genentech and former AVP of Pharmaceutical Strategy and Contracting at Cigna and Express Scripts (now Evernorth)We explore what global market access teams need to know about market access and payer engagement in the US. We  explore how and why value messaging, pricing, and launch strategies are developed differently for the US market, compared to other key launch markets, and what this means for global teams preparing for US launch or taking a US-developed proposition internationally.Learn more at: https://petauri.com/insights/communicating-value-to-us-payers-insights-for-pharma-and-medtech/This episode was first broadcast live as a webinar in March 2025. Learn more about Petauri Evidence: https://petauri.com/petauri-evidence/Learn more about Petauri Advisors: https://petauri.com/petauri-advisors/Meet the ACE team: https://petauri.com/about-us/ace-team/Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

  --------  

  59:02
• Navigating market access: Launch strategies and health economic modelling for medical devices

  Send us a textDiscover how health economics can support successful Medical Device launch, proposition development, and market accessThis episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies when taking new innovations to healthcare leaders, communicating value and demonstrating evidence, and offer tips on leveraging health economics for a successful launch.Juliet Wallace (Senior Partnerships Coordinator) delves deep with our expert panel into the pivotal role of health economic evaluation in supporting market access for medical devices. Juliet puts audience questions to Hannah Palin (Director, Local Market Access), Calum Jones (Associate Director, Health Economics), and Evelyne Priestman (Consultant, Health Economics).See full details at: https://mtechaccess.co.uk/launch-strategies-health-economic-modelling-medical-devices/This episode was originally broadcast live as webinar in February 2025. https://petauri.com/Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

  --------  

  44:41
• Navigating US payer evidence needs to optimise market access

  Send us a textWhat clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek’ of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers’ perspective.They explore:The evolving payer evidence landscape in the USPreferences for clinical and economic evidence by US payersKey differences between the US and other global markets with regard to evidence, HEOR, and market accessOpportunities and challenges when launching new medicines/medical devices/diagnostics in the USInnovative perspectives on evidence planning and strategy for the US marketUS payers’ perspectives, with exclusive insights from Petauri Evidence’s 2024 US payer surveyThis episode was first broadcast as a live webinar in October 2024. Learn more at: https://mtechaccess.co.uk/navigating-us-payer-evidence-needs/Explore more about launching in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

  --------  

  57:34
• Best practice RWE approaches to support economic modelling for HTA

  Send us a textHow can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O’Reilly (Principal Medical Statistician, Arcturis) introduces solutions to these challenges using RWD and RWE approaches. Nick Latimer (Analyst, Delta Hat; Professor of Health Economics, University of Sheffield; former NICE Appraisal Committee member) discusses how RWE is assessed by HTA committees. Samantha Gillard (Director – HTA, Mtech Access) facilitates the discussion and puts your questions to our expertsThis episode was first broadcast as a live webinar in October 2024. To request a copy of the slides used or to learn more visit: https://mtechaccess.co.uk/rwe-approaches-economic-modelling-hta/For support with real-world evidence analysis, health economic modelling of health technology assessment, email [email protected] or visit https://mtechaccess.co.uk/Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

  --------  

  59:53
• NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas

  Send us a textHow is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges.Jo and Karen discuss:How ICBs and Directors of Commissioning prepare for winter pressuresThe current key areas of focus at Place and ICB levelSpecific challenges and pressures facing the NHS now and in the run up to winterImmediate and long-term impact of (expected) new government policiesHow industry can best support the NHS as it plans for winter and beyondHow your field teams can engage with NHS commissioners over the next few monthsThis episode was first broadcast as a live webinar in August 2024.Learn more at https://mtechaccess.co.uk/nhs-winter-planning/For support with your UK market access and NHS engagement strategy, visit: https://mtechaccess.co.uk/strategic-uk-market-access/ or email [email protected] to our newsletter to hear more news, insights and events from Petauri Evidence

  --------  

  1:02:50

Plus de podcasts Sciences

Podcasts tendance de Sciences

À propos de Pharma Market Access Insights - from Petauri Evidence